AstraZeneca to Sell Commercialization Rights of its Two Oncology Candidates to Juvise Pharmaceuticals

 AstraZeneca to Sell Commercialization Rights of its Two Oncology Candidates to Juvise Pharmaceuticals

AstraZeneca Divests Rights of Seroquel and Seroquel XR to Cheplapharm in Europe and Russia

Shots:

  • AstraZeneca to receive up to $181M up front and sales-contingent payments of up to $17M. Juisve to get exclusive commercialization rights for Arimidex (anastrozole) and Casodex (bicalutamide) in a number of European, African and other countries
  • Additionally, in 2017 AstraZeneca divested its rights of Arimidex and Casodex in the US and the therapies have lost their patent protection in above-mentioned countries targeted to treat breast and prostate cancers
  • Arimidex (anastrozole) is an aromatase inhibitor targeted to treat multiple indications of cancer and has generated sales of $37M in 2018. Casodex (bicalutamide) is an androgen-receptor inhibitor administered in combination with a luteinizing hormone-releasing hormone analogue for the treatment of Stage D2 metastatic carcinoma of the prostate

Click here to read full press release/ article | Ref: AstraZeneca | Image: Signbox

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post